1-Pyridin-4-yl-cyclopentanecarboxylic acid | 610791-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-Pyridin-4-yl-cyclopentanecarboxylic acid
• 英文别名: 1-(4-Pyridyl)cyclopentanecarboxylic acid；1-pyridin-4-ylcyclopentane-1-carboxylic acid
• CAS: 610791-44-1
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: PMYJYLQTSHWNJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Pyridin-4-yl-cyclopentanecarboxylic acid 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-3-(2'-Methoxy-biphenyl-4-yl)-2-[(1-pyridin-4-yl-cyclopentanecarbonyl)-amino]-propionic acid
  参考文献：
  名称：

  N-(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists

  摘要：

  A series of potent N-(aralkyl-, arylcycloalkyl-, and heteroaryl-acyl)-4-biphenylalanine VLA-4 antagonists was prepared by rapid analogue methods using solid-phase chemistry. Further optimization led to several highly potent compounds (IC50 < 1 nM). Evaluation of rat pharmacokinetic revealed generally high clearance. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00366-9
• 作为产物：
  描述：

  4-吡啶乙酸乙酯 在 sodium hydroxide 、 potassium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-Pyridin-4-yl-cyclopentanecarboxylic acid
  参考文献：
  名称：

  N-(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists

  摘要：

  A series of potent N-(aralkyl-, arylcycloalkyl-, and heteroaryl-acyl)-4-biphenylalanine VLA-4 antagonists was prepared by rapid analogue methods using solid-phase chemistry. Further optimization led to several highly potent compounds (IC50 < 1 nM). Evaluation of rat pharmacokinetic revealed generally high clearance. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00366-9

文献信息

• General and cost-effective synthesis of 1-heteroaryl/arylcycloalkylamines and their broad applications
  作者：Dehui Zhang、Hongchao Zheng、Xiaodong Wang

  DOI：10.1016/j.tet.2016.02.060

  日期：2016.4

  A general and cost-effective route has been developed to synthesize 1-heteroarylsubstituted cycloalkylamines from readily available heteroarylacetate in good yields. This synthesis features a LHMDS promoted cyclization and one-pot hydrolysis/Curtius rearrangement. This route can be easily carried out on multi-gram scale and be also used to prepare 1-arylsubstituted cycloalkyl/cycloheteroalkylamines

  已经开发了一种通用且成本有效的途径，以容易的产率从易得的杂芳基乙酸酯合成1-杂芳基取代的环烷基胺。该合成具有LHMDS促进环化和一锅水解/柯式重排的特点。该途径可以容易地以克为单位进行，并且还可以用于制备1-芳基取代的环烷基/环杂烷基胺。1-杂芳基/芳基取代的环烷基/环杂烷基胺是通用的构建基块，它们在有机和药物化学中的应用已在吗啉和N-甲基哌嗪类似物以及已知的Rho激酶抑制剂化合物9的合成中得到证明。
• Spirocyclic amides as cannabinoid receptor modulators
  申请人：Hagmann K. William

  公开号：US20050239828A1

  公开（公告）日：2005-10-27

  Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作精神药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合征）及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森氏症、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
  申请人：Merck & Co., Inc.

  公开号：US07423067B2

  公开（公告）日：2008-09-09

  Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作精神药物，治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和格林-巴利综合症）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假梗阻和肝硬化的治疗。
• SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP1490043A2

  公开（公告）日：2004-12-29
• EP1490043A4
  申请人：——

  公开号：EP1490043A4

  公开（公告）日：2007-05-30